Beam Therapeutics' BEAM-301 Eliminates Starch Supplementation in Two Patients in Early Trial

• Beam Therapeutics reported initial Phase 1/2 results for BEAM-301 in six patients with glycogen storage disease type Ia on Oct. 27, 2026.
• Two of three patients receiving 40 mg achieved 15 hours of controlled fasting, eliminating daily starch supplementation at their latest assessments.
• Median fasting tolerance at Day 36 rose from 2.5 to 15 hours with 40 mg, versus 2.9 to 4.3 hours with 20 mg.
• Four of six patients experienced serious treatment-related adverse events; no dose-limiting toxicities occurred.
• Enrollment in the 60 mg cohort is underway; the company plans FDA discussions on a potential approval pathway.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Beam Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610270700PRIMZONEFULLFEED9853626) on October 27, 2026, and is solely responsible for the information contained therein.